Premium
Circadian‐based effects of AcSDKP, with or without rhG–CSF on hematologic toxicity of chemotherapy in mice
Author(s) -
Li XiaoMei,
Soulard Chantai,
Filipski Elisabeth,
Paillette Evelyne Deschamps,
Lévi Francis
Publication year - 1998
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1998.tb01020.x
Subject(s) - toxicity , medicine , pharmacology , chemotherapy , carboplatin , granulocyte colony stimulating factor , endocrinology , granulocyte , chemistry , cisplatin
The hematologic toxicity of arabinosylcytosine (Ara‐C) and carboplatin (CBDCA) as well as the stimulating effect of recombinant human granulocyte colony‐stimulating factor (rhG–CSF) on murine bone marrow vary according to their dosing time along the 24‐h time scale. In the present study, we investigated whether the tolerability of Ara‐C or CBDCA, given at their least toxic circadian time, could be improved further with AcSDKP, a negative regulator of hemopoiesis, rhG–CSF or both. A total of 228 B 6 D 2 F1 mice received once‐daily injection of either Ara‐C (42 mg/kg/d s.c.) for 7 d (d 0–6) at 8 hours after light onset‐HALO) or CBDCA (40 mg/kg/d i.p.) for 5 d (d 2–6) at 16 HALO. AcSDKP (24 μg/d) was continuously infused for 7 d (d 0–6), using an osmotic minipump. rhG–CSF (400 μg/kg/d s.c.) was injected for 4 d (d 9–12) at 9 HALO. Subgroups of mice were sacrificed at 3 HALO on various days following treatment. AcSDKP significantly increased CFU–GM count on d 7 and leukocyte, neutrophil and monocyte counts on d 13 and d 16 compared to Ara‐C alone. Also, rhG–CSF produced similar protective effects to those of AcSDKP with regard to leukocyte and CFU–GM counts. The combination of AcSDKP with rhG‐CSF induced a further increase in total leukocytes and their subsets as compared to either agent alone, but did not alter the CFU–GM counts. Neither AcSDKP nor rhG–CSF nor their combination reduced CBDCA‐induced hematological toxicity. In conclusion, AcSDKP or rhG–CSF administration further improved the tolerability of Ara‐C beyond that already achieved with optimal circadian timing, while no such effect was observed in mice receiving CBDCA at the dose used. The results warrant further exploration of chronopharmacologic delivery schedules combining Ara‐C with AcSDKP.